LOG IN
SIGN UP
MARKET

TARO

TARO

Taro Pharm
NYSE

Real-time Quotes | Nasdaq Last Sale

47.53
-1.04
-2.14%
After Hours: 47.46 0 0.00% 16:01 01/18 EST
OPEN
48.50
PREV CLOSE
48.57
HIGH
48.58
LOW
46.78
VOLUME
20.89K
TURNOVER
--
52 WEEK HIGH
80.00
52 WEEK LOW
45.00
MARKET CAP
1.79B
P/E (TTM)
235.65
1D
5D
1M
3M
1Y
5Y
Taro (TARO) Surges 6.6%: Is This an Indication of Further Gains?
Taro (TARO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks · 01/05 12:48
Hot Stocks: AAPL touches $3T; retailers rally; GILT soars; TARO sets low; APLT drops on delayed application
The same optimistic view that fueled 2021's 27% advance in the S&P 500 carried over into the new year. With investor sentiment remaining strong, the major averages scored modest gains
Seekingalpha · 01/03 22:52
Down More Than 20% YTD, Grab These 3 Buy-Rated Healthcare Stocks for a 2022 Rebound
StockNews.com · 01/02 00:13
The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 12/02/2021 12:51
Taro Pharmaceutical names new finance chief
Taro Pharmaceutical Industries (NYSE:TARO) appoints William J. Coote as Vice President, CFO and Chief Accounting Officer, effective today. Most recently, Mr. Coote has held progressively responsible positions with a variety of global companies
Seekingalpha · 12/01/2021 22:42
Is Taro Pharmaceutical (TARO) A Great Investment Choice?
Raging Capital Management, an investment management firm, published its third-quarter 2021 investor letter – a copy of which can be downloaded here. The fund has compounded its returns at double-digits annually since its inception in 2006, but it plainly d...
Insider Monkey · 11/15/2021 17:15
Taro Pharmaceutical EPS misses by $0.36, misses on revenue
Taro Pharmaceutical (NYSE:TARO): Q3 GAAP EPS of $0.66 misses by $0.36. Revenue of $132M (-7.6% Y/Y) misses by $21.23M. Press Release
Seekingalpha · 10/28/2021 21:32
BRIEF-Taro Pharmaceutical Industries Reports Qtrly Sales Of $132 Million
reuters.com · 10/28/2021 21:17
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TARO. Analyze the recent business situations of Taro Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TARO stock price target is 82.00 with a high estimate of 82.00 and a low estimate of 82.00.
High82.00
Average82.00
Low82.00
Current 47.53
EPS
Actual
Estimate
-0.350.080.510.93
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 130
Institutional Holdings: 5.32M
% Owned: 14.15%
Shares Outstanding: 37.58M
TypeInstitutionsShares
Increased
26
139.04K
New
6
16.81K
Decreased
19
247.24K
Sold Out
10
36.67K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.21%
Pharmaceuticals & Medical Research
-1.37%
Key Executives
Chairman/Director
Dilip Shanghvi
Chief Executive Officer/Director
Uday Baldota
Vice Chairman/Director
Abhay Gandhi
Vice President/General Counsel/Secretary
Erik Zwicker
Vice President/Director of Human Resources
Michele Visosky
Vice President
Victoria Chester
Vice President
Itamar Karsenti
Vice President - Research & Development
Avi Avramoff
Vice President - Business Development
Vikash Agarwal
Other
Jayesh Shah
Director
James Kedrowski
Director
Sudhir Valia
Independent Director
Linda Benshoshan
Independent Director
Dov Pekelman
Independent Director
Robert Stein
Declaration Date
Dividend Per Share
Ex-Div Date
11/05/2018
Dividend USD 0
12/10/2018
11/05/2018
Special Dividend USD 12.81
12/10/2018
  • All
  • Financials
  • Insiders
More
About TARO
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Webull offers kinds of Taro Pharmaceutical Industries Ltd. stock information, including NYSE:TARO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARO stock methods without spending real money on the virtual paper trading platform.